Strategic Report on Non-Alcoholic Steatohepatitis Treatment Market: Growth Opportunities and Emerging Challenges
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Non-Alcoholic Steatohepatitis Treatment Market Valued at Present and by 2029?
The market for treatment of non-alcoholic steatohepatitis has seen a significant increase in size over the recent years. It is projected to rise from $2.6 billion in 2024 to $3.57 billion in 2025, with a compound annual growth rate (CAGR) of 37.5%. The historic development can be linked to factors such as an increase in NASH cases, improved awareness and diagnosis, changes in lifestyle and the obesity crisis, advancements in clinical research, better access to healthcare infrastructure, supportive regulations and clinical trials.
The market size for treatment of non-alcoholic steatohepatitis is projected to witness considerable growth in the upcoming years, escalating to $13.57 billion in 2029 with a compound annual growth rate (CAGR) of 39.6%. The projected growth within the forecast period is a result of improvements in drug development, expanded awareness of the disease, an increase in prevalence and risk factors, and a shift towards personalized medicine. Significant trends anticipated across the forecast period encompass a patient-centered approach, technological advancements, targeted therapies, changes in the regulatory landscape, and advancements in research.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
#What Drivers Are Influencing Growth In The Non-Alcoholic Steatohepatitis Treatment Market?
The growth of the non-alcoholic steatohepatitis treatment market has been pushed forward by a rising prevalence of insulin resistance. This medical issue arises when cells in the muscles, fat, and liver fail to respond correctly to insulin, preventing an easy absorption of glucose from the blood and leading to high blood sugar levels. Unhealthy lifestyle choices, excessive sugar intake, and genetics all play a role in this process. The incidence of insulin resistance has escalated due to an upsurge in diabetes and associated liver ailments, for which non-alcoholic steatohepatitis treatments are used. For example, the Belgium-based International Diabetes Federation reported in January 2022 that diabetes has affected 537 million people aged 20-79 years which accounts for one in every ten individuals. This figure could rise to 643 million by 2030 and 783 million by 2045. Furthermore, in January 2024, the American Cancer Society, a US-based cancer advocacy nonprofit, projected that new liver cancer cases would grow to 41,630 in 2024 from 41,210 in 2023. Hence, the increasing prevalence of insulin resistance due to connected liver and diabetes diseases will spur the growth of the non-alcoholic steatohepatitis treatment market.
What Are The Main Segments Identified In The Non-Alcoholic Steatohepatitis Treatment Market Research?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
What Are The Leading Trends And Opportunities In The Non-Alcoholic Steatohepatitis Treatment Sector?
A prominent trend emerging within the non-alcoholic steatohepatitis treatment landscape is the research and development of non-alcoholic steatohepatitis (NASH) drugs. Numerous corporations are playing a significant role in groundbreaking medicinal innovation, focusing on liver disease treatments with lessened side effects. Notably, in May 2022, Pfizer Inc., a renowned American pharmaceutical and biotech firm, secured a grant from the U.S. Food and Drug Administration (FDA) to accelerate the progression of its NASH drugs, ervogastat and clesacostat. This expedited process, known as Fast Track, aims to streamline the advancement of Pfizer’s experimental combination therapy for treating NASH with liver fibrosis. The medicines in question are ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
Which Companies Play A Key Role In The Development Of The Non-Alcoholic Steatohepatitis Treatment Market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Get The Full Report Here:
What Are The Key Regional Developments Shaping The Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
